Business
neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis)
neffy is the first epinephrine product approved for use out of a hospital setting in China for adults and children (>30 kg) living with severe allergic
About this update from Ars Pharmaceuticals, Inc.
[{"type":"text","content":"neffy is the first epinephrine product approved for use out of a hospital setting in China for adults and children (>30 kg) living with severe allergic reactions Pediatrix Therapeutics, which has a license from ARS Pharma to market neffy in China under the trade name 优敏速®, expects availability in the spring of 2026 SAN DIEGO, Dec. 29, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial-stage biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, announced that the National Medical Products Administration (NMPA) in China has granted approval for neffy 2 mg (epinephrine nasal spray) for the emergency treatment of Type 1 allergic reactions (anaphylaxis) in adults and children who weigh 30 kg or more. In China, the trade name is 优敏速® meaning “Excellent Allergy (treatment) Fast”. ARS Pharma and Pediatrix Therapeutics anticipate filing for approval of neffy 1 mg dose for children greater than 15 kg and less than 30 kg in the coming months. There are currently no approved community use epinephrine products in China, including auto-injectors. Approximately 4.0% to 8.2% of the population of China (about 50 to 100 million people), is estimated to be affected by food allergies and at risk for severe allergic reactions.1 Additionally, for chronic spontaneous urticaria (CSU), which is currently in Phase 2b development by ARS Pharma, 6.5 million people are estimated to be diagnosed and treated with antihistamines or biologics today in China.2 “The approval of neffy in China represents a significant advancement for the millions of patients and caregivers managing severe allergic reactions whose only option until now was to seek emergency medical help without the option to self-administer epinephrine in a community setting,” said Richard Lowenthal, Co-founder, President and CEO of ARS Pharma. “As the first community use epinephrine product available in the Chinese market, neffy has the potential to transform how severe allergies are treated, enabling earlier epinephrine use at the first signs of symptoms and reducing barriers that can delay care. We believe this innovation can meaningfully improve preparedness, confidence, and outcomes for patients and families across China and we look forward to workin...